deferoxamine

Summary

Summary: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Top Publications

  1. Vosjan M, Perk L, Visser G, Budde M, Jurek P, Kiefer G, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-43 pubmed publisher
    ..The entire process of pre-modification, radiolabeling and purification steps will take about 2.5 h...
  2. Cappellini M, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118:884-93 pubmed publisher
    ..trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ? 1 deferasirox dose, 66...
  3. Smith G, Alpendurada F, Carpenter J, Alam M, Berdoukas V, Karagiorga M, et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson. 2011;13:34 pubmed publisher
    ..Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their ..
  4. Jordan L, Vekeman F, Sengupta A, Corral M, Guo A, Duh M. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. J Clin Pharm Ther. 2012;37:173-81 pubmed publisher
    ..Two iron chelating agents are currently available in the United States: Deferoxamine (DFO) is an injectable formulation, and deferasirox (Exjade(®) ) is an oral suspension...
  5. Ruggiero A, Holland J, Lewis J, Grimm J. Cerenkov luminescence imaging of medical isotopes. J Nucl Med. 2010;51:1123-30 pubmed publisher
    ..Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies...
  6. Fine J, Baillargeon A, Renner D, Hoerster N, Tokarev J, Colton S, et al. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1?, and phosphorylates GSK3? in P301L tau transgenic mice. Exp Brain Res. 2012;219:381-90 pubmed publisher
    b>Deferoxamine (DFO), a metal chelator, has been previously reported to slow the loss of spatial memory in a mouse model of amyloid accumulation when delivered intranasally (IN)...
  7. Cassol O, Rezin G, Petronilho F, Scaini G, Gonçalves C, Ferreira G, et al. Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis. Neurochem Res. 2010;35:515-21 pubmed publisher
    ..in the brain of rats after cecal ligation and perforation (CLP) and that a combination of N-acetylcysteine/deferoxamine (NAC/DFX), taurine and RC-3095 were shown to be an effective treatment of sepsis, we investigated whether the ..
  8. Farberg A, Jing X, Monson L, Donneys A, Tchanque Fossuo C, Deshpande S, et al. Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. Bone. 2012;50:1184-7 pubmed publisher
    b>Deferoxamine (DFO) is an iron-chelating agent that has also been shown to increase angiogenesis...
  9. Holland J, Caldas Lopes E, Divilov V, Longo V, Taldone T, Zatorska D, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS ONE. 2010;5:e8859 pubmed publisher
    ..In addition, pharmacodynamic studies on HER2/neu expression levels in response to therapeutic doses of PU-H71 (a specific inhibitor of heat-shock protein 90 [Hsp90]) were conducted...

More Information

Publications62

  1. Li Y, Zhang P, Jin C, Zhou B, Liu X, Tao L, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplant Proc. 2011;43:1450-5 pubmed publisher
    b>Deferoxamine mesylate is known to ameliorate tissue ischemia-reperfusion injury...
  2. Pless G, Sauer I, Rauen U. Improvement of the cold storage of isolated human hepatocytes. Cell Transplant. 2012;21:23-37 pubmed publisher
    ..Cold-induced injury could be significantly reduced by the addition of the iron chelators deferoxamine and LK 614...
  3. Kolnagou A, Kleanthous M, Kontoghiorghes G. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin. 2011;35:186-98 pubmed publisher
    The international committee on chelation (ICOC) of deferiprone (L1) and deferoxamine (DFO) combination therapy was the first protocol reported to have achieved normal range body iron store levels (NRBISL) in ?-thalassemia major (?-TM) ..
  4. Wu Y, Li X, Xie W, Jankovic J, Le W, Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010;57:198-205 pubmed publisher
    ..b>Deferoxamine is one of iron chelators that may accumulate HIF-1 alpha due to the decreased degradation of HIF-1 alpha via ..
  5. Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, et al. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab. 2012;302:E77-86 pubmed publisher
    ..Eight-week-old KKAy mice were divided into two groups and treated with deferoxamine (DFO), an iron chelator agent, or a vehicle for 2 wk...
  6. Pepe A, Meloni A, Rossi G, Cuccia L, D Ascola G, Santodirocco M, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013;15:1 pubmed publisher
    ..was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow ..
  7. Febbraro F, Andersen K, Sanchez Guajardo V, Tentillier N, Romero Ramos M. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the ?-synuclein rAAV Parkinson's model. Exp Neurol. 2013;247:45-58 pubmed publisher
    ..Here, we investigate the possible neuroprotective effect of the iron chelator deferoxamine in vivo to elucidate whether iron chelation can provide meaningful therapy for Parkinson's disease...
  8. Kolnagou A, Kleanthous M, Kontoghiorghes G. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85:430-8 pubmed publisher
    ..New chelating drug protocols are necessary to treat completely transfusional iron overload and eliminate associated toxicity. Appropriate deferiprone/deferoxamine combinations could achieve this goal.
  9. Donneys A, Deshpande S, Tchanque Fossuo C, Johnson K, Blough J, Perosky J, et al. Deferoxamine expedites consolidation during mandibular distraction osteogenesis. Bone. 2013;55:384-90 pubmed publisher
    ..b>Deferoxamine (DFO) is an angiogenic activator that triggers the HIF-1? pathway through localized iron depletion...
  10. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86:433-6 pubmed publisher
    The Thalassemia Clinical Research Network collected adherence information from 79 patients on deferoxamine and 186 on deferasirox from 2007 to 2009...
  11. Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010;123:148-52 pubmed publisher
    There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction...
  12. Zhang L, Hu R, Li M, Li F, Meng H, Zhu G, et al. Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury. Neurol Sci. 2013;34:639-45 pubmed publisher
    This study investigated whether deferoxamine (DFO), an iron chelator attenuates iron-induced toxicity in rats with traumatic brain injury. In this study, three groups of Sprague-Dawley rats (sham, injury and DFO groups) were examined...
  13. Baek J, Reiter C, Manalo D, Buehler P, Hider R, Alayash A. Induction of hypoxia inducible factor (HIF-1?) in rat kidneys by iron chelation with the hydroxypyridinone, CP94. Biochim Biophys Acta. 2011;1809:262-8 pubmed publisher
    ..In conclusion, we have identified the inhibition of iron-binding pocket of PHD as an underlying mechanism of HIF induction in vivo and in vitro by a bidentate hydroxypyridinone...
  14. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96:41-7 pubmed publisher
  15. Zhao Y, Rempe D. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab. 2011;31:1412-23 pubmed publisher
    ..Prolyl hydroxylase inhibitors (PHIs), such as deferoxamine (DFO), reduce stroke volume when administered at high doses in the peristroke period, which is largely mediated ..
  16. Ikeda Y, Tajima S, Yoshida S, Yamano N, Kihira Y, Ishizawa K, et al. Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis. 2011;215:339-47 pubmed publisher
    b>Deferoxamine (DFO), an iron chelator for disorders of excess iron, upregulates the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2), indicating that it affects angiogenesis...
  17. Guo C, Wang T, Zheng W, Shan Z, Teng W, Wang Z. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:562-75 pubmed publisher
    ..We evaluated the effects of intranasal administration of the high-affinity iron chelator deferoxamine (DFO) on A? neuropathology and spatial learning and memory deficits created in this AD model...
  18. Chen J, Marks E, Lai B, Zhang Z, Duce J, Lam L, et al. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS ONE. 2013;8:e77023 pubmed publisher
    ..Finally, we show that intra-ventricular delivery of the iron chelator deferoxamine results in an improvement of the motor phenotype in R6/2 HD mice...
  19. Selim M, Yeatts S, Goldstein J, Gomes J, Greenberg S, Morgenstern L, et al. Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011;42:3067-74 pubmed publisher
    Treatment with the iron chelator, deferoxamine mesylate (DFO), improves neurological recovery in animal models of intracerebral hemorrhage (ICH)...
  20. Vlahakos D, Arkadopoulos N, Kostopanagiotou G, Siasiakou S, Kaklamanis L, Degiannis D, et al. Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. Artif Organs. 2012;36:400-8 pubmed publisher
    We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute ..
  21. Najafi R, Sharifi A. Deferoxamine preconditioning potentiates mesenchymal stem cell homing in vitro and in streptozotocin-diabetic rats. Expert Opin Biol Ther. 2013;13:959-72 pubmed publisher
    ..There is evidences showing that deferoxamine (DFO), an iron chelator, increases the mobilization and homing of progenitor cells through increasing the ..
  22. Pantalone G, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients. Hemoglobin. 2011;35:206-16 pubmed publisher
    ..Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1)...
  23. Guo C, Wang P, Zhong M, Wang T, Huang X, Li J, et al. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int. 2013;62:165-72 pubmed publisher
    ..More importantly, elucidation of DFO mechanism in suppressing tau phosphorylation may provide insights for developing therapeutic strategies to combat AD...
  24. Molina Jijón E, Zarco Márquez G, Medina Campos O, Zatarain Barrón Z, Hernandez Pando R, Pinzón E, et al. Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation. Toxicology. 2012;291:93-101 pubmed publisher
    b>Deferoxamine (DFO) is a recognized iron chelator which has been shown to exert nephroprotection in models of toxic nephropathies...
  25. Najafzadeh H, Jalali M, Morovvati H, Taravati F. Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat. J Med Toxicol. 2010;6:22-6 pubmed publisher
    ..In this study, the prophylactic effect of deferoxamine and silymarin was compared in decreasing experimental iron-overload-induced hepatotoxicity in rats...
  26. Alpendurada F, Smith G, Carpenter J, Nair S, Tanner M, Banya W, et al. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson. 2012;14:8 pubmed publisher
    Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF)...
  27. Okauchi M, Hua Y, Keep R, Morgenstern L, Schallert T, Xi G. Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke. 2010;41:375-82 pubmed publisher
    b>Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats. Our previous study found that 50 mg/kg is an effective dose in aged rats...
  28. Lee J, Keep R, He Y, Sagher O, Hua Y, Xi G. Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. J Cereb Blood Flow Metab. 2010;30:1793-803 pubmed publisher
    ..hemorrhage (SAH), examine the relationship between iron and neuroglial cell changes, and determine whether deferoxamine (DFX) can reduce SAH-induced injury...
  29. Donneys A, Weiss D, Deshpande S, Ahsan S, Tchanque Fossuo C, Sarhaddi D, et al. Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy. Bone. 2013;52:318-25 pubmed publisher
    ..Experimental studies have shown that deferoxamine (DFO), an iron-chelating agent, bolsters vascularity and subsequently enhances normal fracture healing when ..
  30. Carpenter J, Alpendurada F, Deac M, Maceira A, Garbowski M, Kirk P, et al. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. J Cardiovasc Magn Reson. 2010;12:24 pubmed publisher
    ..We aimed to define reference ranges for right ventricular (RV) volumes, ejection fraction (EF) in thalassemia major patients (TM) without myocardial iron overload...
  31. Klettner A, Koinzer S, Waetzig V, Herdegen T, Roider J. Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. Cutan Ocul Toxicol. 2010;29:122-9 pubmed publisher
    b>Deferoxamine mesylate is clinically used as a chelating agent but might induce retinopathy. To evaluate its effect on the retinal pigment epithelium (RPE), porcine RPE cells were stimulated with deferoxamine...
  32. Paterniti I, Mazzon E, Emanuela E, Paola R, Galuppo M, Bramanti P, et al. Modulation of inflammatory response after spinal cord trauma with deferoxamine, an iron chelator. Free Radic Res. 2010;44:694-709 pubmed publisher
    The standard iron-chelator deferoxamine is known to reduce neurological deficits...
  33. Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, et al. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. Eur J Haematol. 2010;85:36-42 pubmed publisher
    ..We retrospectively evaluated the efficacy of different schedules of combined chelation therapy and the incidence of adverse events...
  34. Valdes P, Samkoe K, O Hara J, Roberts D, Paulsen K, Pogue B. Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol. 2010;86:471-5 pubmed publisher
    ..Mice implanted with xenograft U251-GFP glioma tumor cells were given a 200 mg kg(-1) dose of deferoxamine (DFO), once a day for 3 days prior to delta-ALA administration...
  35. Jiang X, Malkovskiy A, Tian W, Sung Y, Sun W, Hsu J, et al. Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles. Biomaterials. 2014;35:803-813 pubmed publisher
    ..b>Deferoxamine mesylate (DFO) is an FDA-approved iron chelator which has been shown to upregulate cellular HIF-1α...
  36. Zarogiannis S, Jurkuvenaite A, Fernandez S, Doran S, Yadav A, Squadrito G, et al. Ascorbate and deferoxamine administration after chlorine exposure decrease mortality and lung injury in mice. Am J Respir Cell Mol Biol. 2011;45:386-92 pubmed publisher
    ..Ascorbate and deferoxamine were administered intramuscularly every 12 hours and by nose-only inhalation every 24 hours for 3 days starting ..
  37. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487-94 pubmed
    ..This retrospective survey investigated relationships between iron overload, chelation practices, and morbidity/mortality in patients with these diseases...
  38. Jin H, Terai S, Sakaida I. The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis. J Gastroenterol. 2007;42:475-84 pubmed
    Hepatic stellate cells (HSCs) play a pivotal role in liver fibrogenesis. Here, we studied whether the iron chelator deferoxamine (DFO) affected cultured HSC activation and apoptosis.
  39. Hishikawa T, Ono S, Ogawa T, Tokunaga K, Sugiu K, Date I. Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. Neurosurgery. 2008;62:232-40; discussion 240-1 pubmed publisher
    ..the relationship between HIF-1 expression and subarachnoid hemorrhage (SAH) and to characterize the effects of deferoxamine (DFO)-induced increases in HIF-1 protein levels on the brainstem and the basilar artery (BA) after experimental ..
  40. Kim B, Chung H. Desferrioxamine (DFX) induces apoptosis through the p38-caspase8-Bid-Bax pathway in PHA-stimulated human lymphocytes. Toxicol Appl Pharmacol. 2008;228:24-31 pubmed publisher
    ..Our results suggest that DFX-induced apoptosis is mediated by the p38 pathway and a caspase-8-dependent Bid-Bax pathway in human lymphocytes...
  41. Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail. 2007;9:320-2 pubmed
  42. Kontoghiorghes G, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin. 2009;33:386-97 pubmed publisher
    ..In contrast to L1, both deferoxamine (DFO) and deferasirox (DFRA) have major disadvantages in their use in non iron loading conditions due to ..
  43. Li L, Frei B. Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol. 2009;29:732-8 pubmed publisher
    ..The objective of the present study was to investigate whether and how LPS and iron enhance, and DFO inhibits, NADPH oxidase activity in human aortic endothelial cells (HAECs)...
  44. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145:245-54 pubmed publisher
    ..randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone-deferoxamine (DFO-DFP) versus DFP alone to treat thalassaemia major (TM)...
  45. Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol. 2008;119:133-41 pubmed publisher
    ..However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires parenteral infusions that can negatively impact quality of life and adherence to treatment.
  46. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008;172:738-47 pubmed publisher
    ..This study investigated the effect of iron depletion by deferoxamine on insulin signaling and glucose uptake in HepG2 hepatocytes and in rat liver...
  47. Cohen A, Glimm E, Porter J. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111:583-7 pubmed
    ..or negative iron balance was assessed in patients receiving different doses of deferasirox and the comparator deferoxamine. After dose adjustment, reductions in LIC after 1 year of deferasirox or deferoxamine therapy correlated with ..
  48. Teixeira K, Soares F, Rocha L, Silveira P, Silva L, Valença S, et al. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther. 2008;21:309-16 pubmed
    ..This study examines the effect of N-acetylcysteine (NAC) and deferoxamine (DFX) on inflammatory indicators and oxidative stress in the lungs of mice exposed to bleomycin (BLM)...
  49. Martin M, Arcasoy M. Deferasirox versus deferoxamine. Blood. 2006;108:774-5; author reply 775-6 pubmed
  50. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A, et al. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol Trace Elem Res. 2009;132:184-96 pubmed publisher
    ..by doxorubucin (DOX) and to compare the possible protective effects of N-acetylcysteine (NAC) (n=10), deferoxamine (DOF) (n=10), DOF+NAC (n= 10) and selenium (n=9) on doxorubicin-induced hepatotoxicity...
  51. Perk L, Vosjan M, Visser G, Budde M, Jurek P, Kiefer G, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250-9 pubmed publisher
    ..To enable widespread use of (89)Zr-immuno-PET, we now introduce the novel BFC p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) and compare its performance in (89)Zr-immuno-PET with the reference BFC TFP-N-sucDf...
  52. Warkentin L, Auriat A, Wowk S, Colbourne F. Failure of deferoxamine, an iron chelator, to improve outcome after collagenase-induced intracerebral hemorrhage in rats. Brain Res. 2010;1309:95-103 pubmed publisher
    Intracerebral hemorrhage (ICH) is a devastating stroke with no clinically proven treatment. Deferoxamine (DFX), an iron chelator, is a promising therapy that lessens edema, mitigates peri-hematoma cell death, and improves behavioral ..
  53. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148:466-75 pubmed publisher
    ..These results suggest that intensive combined chelation normalized patients' iron load and thereby prevented and reversed cardiac and multiple endocrine complications associated with transfusion iron overload...